A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia

Conclusion: These results suggest that low doses of D1 agonists that do not result in measureable occupancy of the D1R do not reliably improve cognition in SCZ, unlike the observations in NHP. As this drug is limited by its pharmacokinetic profile, better D1R agonists that can achieve adequate levels of D1R occupancy are needed to test the efficacy of this mechanism for cognitive enhancement in SCZ.

http://jop.sagepub.com/cgi/content/abstract/30/5/428?rss=1

Source: Journal of Psychopharmacology - April 18, 2016 Category: Psychiatry Authors: Girgis, R. R., Van Snellenberg, J. X., Glass, A., Kegeles, L. S., Thompson, J. L., Wall, M., Cho, R. Y., Carter, C. S., Slifstein, M., Abi-Dargham, A., Lieberman, J. A. Tags: Original Papers Source Type: research